Exeliom Biosciences

Everything started with Pr. Harry Sokol (Professor at the Gastroenterology department of the Saint Antoine Hospital) and his observations on patients. After comparing the gut microbiome from Inflammatory Bowel Diseases (IBD) patients and healthy subjects, he and his team identified our star bacterium Faecalibacterium prausnitzii as a key player of our health. In other words, they discovered that patients suffering from inflammatory bowel diseases simply do not have the microbiome it takes to fight their conditions. That was a new dawn in this field of inflammatory bowel diseases and in the field of microbiome.

Pr. Sokol then partnered with Dr. Philippe Langella’s team (Research Director at the French National Institute of Agricultural Research) to study the yet unexplored anti-inflammatory properties of Faecalibacterium prausnitzii. Together, they managed to isolate and select the right strain to initiate the work on a new type of drug candidates.

Pr. Patrick Gervais (Emeritus Professor of Process Engineering at AgroSup Dijon) brought his world-renowned expertise in the development of extremely-oxygen sensitive bacteria to the mission. Together, the team joined forces to take up the challenge of growing such fastidious strains in a robust manner, which is the next frontier in the field of microbiome-based therapeutics. We were the first to cross it.A 7-million Series A funding was raised in 2018 to jump start the journey and more than 15 million euros have been secured since then to fuel in our lead program EXL01, build a state-of-the-art manufacturing pilot unit and develop our pipeline.

After years spent developing our therapeutic solution, we are coming back to where it all started, the patients, for our first clinical trial.

It’s time for a change. We are not here to curse the traditional pharmaceutical ways.

We are here to light a candle.

“If we open a quarrel between the future and the past, we shall be in danger of losing the future.” Winston Churchill

Today, our concern must be the future. Your future.

Our future. For the world is changing and the people with it.

That’s why our mission is to bring the microbiome to the traditional pharma.

Our mission revolves around three ideas

observing..
Exeliom Biosciences’ approach is rooted in a strong clinical rationale that makes it worth the journey to explore new microbiome fields and overcome their challenges. This rationale derives from a thorough and tireless observation of the patients’ conditions.

to cross the next frontier..
While companies developing single bacterial-strain therapies have been focusing on low-hanging fruits until now, Exeliom Biosciences took up the challenge to unlock the therapeutic potential of one of the most fastidious and promising gut bacteria: Faecalibacterium prausnitzii (F. prau). We have cultured the unculturable and we have made it possible to conceive a well-defined and purified drug exploiting the remarkable properties of this star gut bacterium.

and give you a fair chance to fight
Our thinking is deeply rooted in you, the patients. Our first mission is to overcome the obstacles associated with highly promising, yet fastidious, bacteria. Then, we will make an F. prau-based drug for you. This drug is to give you the same resources as healthy subjects so that your body can fight.

At Exeliom Biosciences, we are driven by strong values involved in every single decision we make.

supportive of one another to overcome challenges together

respectful of all the people involved in this journey,
be they patients, physicians, team members, partners or stakeholders

fearless
on a mission to cross the next frontier

It is time for a new generation of medicine.
It is time to harness our body’s therapeutic properties. It is time to give you a fair chance to fight. It is time to cross the next frontier and nourish the hopes that you have for your own future.